
Meet Devin: Goldman Sachs' new AI software engineer that never sleeps
Goldman Sachs just 'hired' an AI software engineer made by the startup Cognition.
Goldman Chief Information Officer Marco Argenti told CNBC that the company plans to 'augment' its workforce with the AI tool, which will execute tasks on behalf of its more than 10,000 human software developers. 'Initially, we will have hundreds of Devins [and] that might go into the thousands, depending on the use cases,' Argenti said.
Wall Street has been wading in and exploring AI in the last couple of years, but Goldman's push to integrate autonomous AI agents might be the finance sector's first plunge into the deep end.
A brief history of Devin
Cognition introduced the technology, which it hailed as the world's 'first AI software engineer,' last year. That tech, known as Devin, was designed to execute software engineering tasks independently, making thousands of decisions along the way. Using natural language prompts, programmers can put Devin to work doing complex tasks like building an app or finding and fixing bugs in a codebase.
Cognition describes Devin as a 'a tireless, skilled teammate, equally ready to build alongside you or independently complete tasks for you to review' – a description as likely to strike fear in the hearts of workers as it is to have executives seeing dollar signs. Shortly after its launch, the founder of prominent AI search engine Perplexity praised Cognition's Devin as the first AI agent 'that seems to cross the threshold of what is human level and works reliably.'
The company was valued at $4 billion in March after raising hundreds of millions in investment led by 8VC, an early stage venture capital firm founded by Palantir co-founder Joe Lonsdale. Cognition is obviously leaning on Devin's anthropomorphic branding to generate buzz and make Devin feel like a one to one substitute for a human that can write code, but so far that strategy seems to be working.
Like most promising new technologies, the marketing doesn't always match reality – at least not yet. When one group of data scientists put Devin to the test, they found that the AI software engineer only successfully completed three of 20 proposed tasks, with 14 of the test projects being total flops. In benchmark tests, Devin performed twice as well as an LLM-based chatbot, but didn't deliver on the promise of operating fully autonomously.
AI-generated code can also pose its own problems for companies, with bugs leading to downtime and security risks being glossed over due to less human involvement in the process.
What is agentic AI?
Agentic AI is yet another AI buzzword, but it does mean something specific. Unlike chatbots or AI research tools that people are most likely to interact with, agentic AI is designed to execute tasks and make decisions on its own without constant human input (hence the emphasis on agency in 'agentic').
The ability to execute multi-step jobs from start to finish means these tools work more how humans do, pursuing set goals and completing various kinds of tasks to get there. While generative AI is focused on generating outputs, like writing a draft email or compiling research, agentic AI is all about executing tasks and taking action, though how those systems accomplish that and the degree to which they are successful is up to their design.
Wall Street wades in
Goldman Sachs seems to be the only major bank implementing a start-to-finish AI coding tool like Devin, but its competitors likely aren't far behind. AI assistants and chatbots are used widely on Wall Street already as big banks look for a competitive edge and pour investment into AI-related hires and technology.
JPMorgan Chase introduced its own generative AI assistant internally last year, making the tool available to 60,000 employees who can leverage it to write emails and file reports. Morgan Stanley similarly provided financial advisors with internal tools running OpenAI's tech under the hood.
'We are completely convinced the consequences will be extraordinary and possibly as transformational as some of the major technological inventions of the past several hundred years,' JPMorgan Chase CEO Jamie Dimon said in bullish comments on AI last year, adding that he expects the technology to 'augment virtually every job.'
While AI chatbots and other lower-level tools are approaching ubiquity, adoption of agentic AI isn't there yet. In a report last year, Deloitte predicted that a quarter of companies already using generative AI would begin exploring agentic AI in 2025, but risks from the technology's relative lack of human oversight means companies will move more slowly to fully implement it.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Dell, Nvidia, and Elastic Join Forces to Supercharge AI Workloads
Aug 12 - Dell Technologies (NYSE:DELL) is teaming up with Nvidia (NASDAQ:NVDA) and Elastic (NYSE:ESTC) to supercharge its AI Data Platform, designed for industries from media and entertainment to finance. The goal is to make it easier for enterprises to build, deploy, and scale AI at lightning speed. Dell's Vrashank Jain calls the platform built for a world where data is gold, pointing to its ability to break down data silos, accelerate workflows, and create richer AI-enabled experiences. Under the hood, Dell PowerEdge R7725 servers paired with Nvidia's RTX PRO 6000 Blackwell Server Edition GPUs deliver serious computing muscle. Warning! GuruFocus has detected 5 Warning Signs with NVDA. Elastic brings its Elasticsearch tech to the table, enabling natural language and vector search. Editors can now pinpoint a scene instantly without digging through endless folders. Nvidia's Omniverse libraries and AI models take it further, streamlining searches through massive 3D asset libraries. Whether in film production or real-time financial analytics, Dell claims the platform accelerates processing, communication and storage of low-latency, high-performance AI workloads. This tripartite co-operation could be a shortcut to greater AI-based efficiency that companies crave. This article first appeared on GuruFocus.
Yahoo
3 minutes ago
- Yahoo
Delta, Aeromexico request extension to wrap up antitrust agreement
MEXICO CITY (Reuters) -Carriers Delta and Aeromexico on Tuesday argued against winding down their antitrust agreement, as proposed by the U.S. Department of Transportation, while asking for an extension to do so if needed. The two, in a filing to authorities, requested the deadline be extended to March 28 of next year, the end of the sector's "winter season," from the current October 25. Sign in to access your portfolio
Yahoo
3 minutes ago
- Yahoo
Global High-Throughput Screening Market to Surpass USD 50.2 Billion by 2029
Delray Beach, FL, Aug. 12, 2025 (GLOBE NEWSWIRE) -- North America Leads Today, Asia Pacific to Record Fastest GrowthThe global high throughput screening market, valued at US$25.7 billion in 2023, stood at US$28.8 billion in 2024 and is projected to advance at a resilient CAGR of 11.8% from 2024 to 2029, culminating in a forecasted valuation of US$50.2 billion by the end of the period. This growth is propelled by surging R&D investments in drug discovery, strategic government funding, and the increasing adoption of automation in life sciences research. Download PDF Brochure: What Is Driving the Market Now?HTS adoption is accelerating due to innovations in automation, miniaturization, and high-content screening, which significantly reduce discovery timelines and enhance precision in identifying therapeutic candidates. Grants such as the USD 7.8 million awarded to the University of Pittsburgh for advanced drug discovery systems underscore growing institutional and government commitment to high-impact research. Why Does This Matter for Global Pharma and Biotech Leaders?The market represents a critical enabler for competitive advantage in lead discovery, target validation, compound profiling, and hit identification—processes essential for pipeline acceleration. While high instrument costs remain a barrier, particularly for automated liquid handling and high-resolution imaging systems, emerging markets such as China and India offer lucrative opportunities with strong government support and an expanding pharmaceutical manufacturing base. Who Are the Key Stakeholders?The HTS ecosystem spans pharmaceutical giants, biotechnology innovators, academic institutions, and technology providers, all collaborating to enhance assay development and manage the rising complexity of biological data. The consumables segment—driven by recurring purchases of reagents and kits—dominates the market, ensuring steady demand as HTS workflows expand globally. Request Sample Pages: Where Is Growth Coming From? North America currently leads, fueled by advanced HTS infrastructure, robust funding for life science research, and a thriving biotech sector. Asia Pacific is projected to be the fastest-growing region, supported by a diverse patient base, strong pharmaceutical capabilities, and favorable regulatory environments. How Are Market Leaders Responding? Thermo Fisher Scientific Inc. maintains global leadership through an extensive portfolio of automated systems, screening instruments, and consumables, underpinned by 3% annual R&D investment and strategic alliances. Agilent Technologies, Inc. offers highly customizable workflows via BioTek detection instruments and Gen6 software, strengthened by acquisitions such as e-MSion (US) to enhance mass spectrometry capabilities. Merck KGaA delivers a diverse portfolio of reagents, instruments, software, and services, leveraging global reach and deep customer relationships across pharma, academia, and government sectors. Market OutlookAs automation, AI-driven data analysis, and advanced assay development converge, HTS will remain at the forefront of pharmaceutical innovation. Decision-makers who strategically invest in HTS capabilities today will be best positioned to accelerate therapeutic pipelines, capture market share, and deliver faster, more targeted treatments to market. For more information, Inquire Now Discover Connected Healthcare Market Opportunities:Drug Screening MarketCarrier Screening MarketCell based Assays MarketLabel Free Detection MarketLife Science Instrumentation Market Get access to the latest updates on High-Throughput Screening Companies and High-Throughput Screening Market Size CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445, USA: +1-888-600-6441 Email: sales@ Visit Our Website: while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data